A method is disclosed for the treatment of migraine by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.
A method is disclosed for the treatment of depression by the administration of 3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.
Intermediates in the synthesis of chroman derivatives
申请人:Astra Aktiebolag
公开号:US05646309A1
公开(公告)日:1997-07-08
Compounds of the formula ##STR1## are disclosed. These compounds are employed as intermediates in the synthesis of aminochroman compounds useful in the treatment of CNS disorders.
Process for preparing (R)-3-amino-5-methoxychroman
申请人:Astra Aktiebolag
公开号:US05650524A1
公开(公告)日:1997-07-22
A process for preparing (R)-3-amino-5-methoxychroman is provided. The process comprises the steps of (i) dissolving racemic 3-amino-5-methoxychroman and L(+)tartaric acid in water to form the tartrate salt; (ii) heating the solution until a clear solution is obtained; and (iii) crystallizing the tartrate salt by allowing the solution to cool to room temperature.
A method is disclosed for the treatment of anxiety by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.